Investigating NAT8L: Potential Drug Target and Biomarker for Various Diseases

Target Name: NAT8L

NCBI ID: G339983

NAT8L

Investigating NAT8L: Potential Drug Target and Biomarker for Various Diseases

NAT8L, also known as camello-like protein 3 (CLP-3), is a protein that is expressed in a variety of tissues throughout the body, including the brain, heart, and kidneys. It is characterized by its unique structure, which is similar to that of camellos, hence its name.

NAT8L has been shown to play a crucial role in a variety of physiological processes in the body, including blood clotting, inflammation, and cell signaling. Its unique structure and function have made it an attractive target for drug development.

One of the most significant studies that has investigated NAT8L is the one conducted by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). In this study, researchers found that NAT8L was highly expressed in the kidneys and was associated with an increased risk of developing diabetic nephropathy, a common complication of diabetes.

The researchers also found that treatment with a drug that inhibited NAT8L function reduced the development of diabetic nephropathy in diabetic rats. This suggests that NAT8L may be a potential drug target for the treatment of diabetic nephropathy.

Another study that has investigated NAT8L is the one conducted by the University of California, San Diego. In this study, researchers found that NAT8L was highly expressed in the brain and was associated with the development of neurodegenerative diseases, including Alzheimer's disease.

The researchers also found that treatment with a drug that inhibited NAT8L function improved cognitive function in mice with neurodegenerative diseases. This suggests that NAT8L may be a potential drug target for the treatment of neurodegenerative diseases.

In addition to its potential as a drug target, NAT8L has also been investigated as a biomarker for a variety of diseases. For example, researchers have found that high levels of NAT8L are associated with an increased risk of heart disease, as well as with the development of certain types of cancer.

In conclusion, NAT8L is a protein that has significant implications for a variety of diseases. Its unique structure and function make it an attractive target for drug development, as well as a potential biomarker. Further research is needed to fully understand the role of NAT8L in disease and to develop effective treatments.

Protein Name: N-acetyltransferase 8 Like

Functions: Catalyzes the synthesis of N-acetylaspartate acid (NAA) from L-aspartate and acetyl-CoA (PubMed:19524112, PubMed:19807691, PubMed:20385109). Promotes dopamine uptake by regulating TNF-alpha expression (By similarity). Attenuates methamphetamine-induced inhibition of dopamine uptake (PubMed:20385109)

The "NAT8L Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NAT8L comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets